Its major product is a continuous glucose monitoring (CGM) system for people suffering from diabetes. The CGM system enables real-time continuous blood monitoring which is then transferred to a user's smart device.;

DexCom Inc. sells its products directly or through distributors in the United States and internationally.

The company's market capitalization is currently estimated at $39.79 billion. Over the past year, it posted revenue of $2.448 billion and a net profit of $154.7 million.

DexCom Inc. shares and what affects their value;

The shares of DexCom Inc. have been trading on the NASDAQ stock exchange under the ticker “DXCM” since 2005. The initial price of one share was $12.

At the moment, the stock is trading in the range between $99 and $103. Over the past year, the stock price fluctuated between a low of $66 and a high of $165.

What to consider when trading the asset:

The company has a good reputation and a brand that is recognized across the world;
Strong international presence;
The company develops its own mobile apps and prioritizes innovative technologies;
DexCom Inc. had no competitors for quite a long time. Today, however, other medical companies have presented a similar device and may easily claim its share in the market;
Strong competition forces the company to cut production costs and fight for customers’ attention by constantly improving its products;
The ability to collect data from patients using the company’s devices enables DexCom Inc. to develop personalized treatment plans.